ストックスクリーナーアプリを入手
4.32
2.86%
0.12
前日終値:
$4.20
開ける：
$4.22
24時間の取引高:
1.01M
Relative Volume:
1.38
時価総額：
$242.80M
収益：
-
当期純損益:
$-57.44M
株価収益率:
-3.2333
EPS:
-1.3361
ネットキャッシュフロー:
$-56.46M
1週間 パフォーマンス:
+6.40%
1か月 パフォーマンス:
+14.29%
6か月 パフォーマンス:
-24.87%
1年 パフォーマンス:
+38.46%
1日の値動き範囲:
$4.08
$4.37
1週間の範囲:
$4.015
$4.49
52週間の値動き範囲:
$2.97
$7.82
Protara Therapeutics Inc Stock (TARA) Company Profile
名前
Protara Therapeutics Inc
セクター
電話
646-844-0337
住所
345 PARK AVENUE SOUTH, NEW YORK, NY
Compare TARA vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TARA
Protara Therapeutics Inc
|
4.32 | 242.80M | 0 | -57.44M | -56.46M | -1.3361 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-04 | 開始されました | JP Morgan | Overweight |
| 2026-01-07 | 開始されました | Piper Sandler | Overweight |
| 2025-04-16 | 開始されました | Scotiabank | Sector Outperform |
| 2025-03-14 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-07-10 | 再開されました | Guggenheim | Buy |
| 2021-06-04 | 開始されました | H.C. Wainwright | Buy |
| 2021-02-17 | 開始されました | Oppenheimer | Outperform |
| 2020-10-19 | 開始されました | Cowen | Outperform |
| 2020-07-29 | 開始されました | Guggenheim | Buy |
すべてを表示
Protara Therapeutics Inc (TARA) 最新ニュース
What's Driving Protara's Recent Surge - Kavout | AI
Millennium Group and Israel Englander report 5.7% stake in Protara (TARA) - Stock Titan
Protara Therapeutics focuses on rare disease programs as development continues - ad-hoc-news.de
Enterprise value to EBITDA forward of Protara Therapeutics, Inc. – NASDAQ:TARA - TradingView
Protara Therapeutics, Inc. Actuals & Estimates (HAM:1KPA) - TradingView
uniQure, Protara, Abeona, Cerebras, Verisign Insider Shake-Up - TipRanks
Protara Therapeutics (TARA) Holds Steady Near Support, Faces Resistance at $4.26Debt Free Companies - dars.gov.et
Protara Therapeutics (TARA) CEO exercises options, sells 215,687 shares and makes 30,000-share gifts - Stock Titan
Enterprise value to EBITDA forward of Protara Therapeutics, Inc. – GETTEX:1KPA - TradingView
Does TARA Stock’s 15% After-Hours Slump Signal A Bargain After New Bladder Cancer Data? - Stocktwits
Protara Therapeutics, Inc. Files Form 8-K with NASDAQ Listing and Company Details (2026) - Minichart
Form 144 PROTARA THERAPEUTICS For: 29 June By Investing.com - Investing.com South Africa
Protara Therapeutics Announces Key Medical Leadership Transition - TipRanks
Protara Therapeutics (TARA) CMO Leonardo Nicacio resigns, duties reassigned - Stock Titan
[144] Protara Therapeutics, Inc. SEC Filing - Stock Titan
TARAProtara Therapeutics Inc Options - Finviz
Protara Therapeutics, Inc. Actuals & Estimates (MUN:1KPA) - TradingView
Protara Therapeutics, Inc. Actuals & Estimates (SWB:1KPA) - TradingView
Enterprise value to revenue forward of Protara Therapeutics, Inc. – NASDAQ:TARA - TradingView
Protara Therapeutics, Inc. Actuals & Estimates (FWB:1KPA) - TradingView
Enterprise value to revenue forward of Protara Therapeutics, Inc. – FWB:1KPA - TradingView
TARA Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of Protara Therapeutics, Inc. – NASDAQ:TARA - TradingView
Price to sales forward of Protara Therapeutics, Inc. – NASDAQ:TARA - TradingView
Protara Therapeutics Inc (TARA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Protara Therapeutics Inc (TARA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Analysts Offer Insights on Healthcare Companies: Odyssey Therapeutics, Inc. (ODTX), Capricor Therapeutics (CAPR) and Medtronic (MDT) - The Globe and Mail
Protara Therapeutics Inc (TARA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Protara Therapeutics Inc (TARA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Protara Therapeutics Inc (TARA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Protara Therapeutics Inc (TARA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Protara Therapeutics Inc (TARA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Protara Therapeutics Inc (TARA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Protara Therapeutics Inc (TARA) Institutional Confidence - TradingKey
Protara (TARA) director granted 31,000 stock options at $3.94 strike - Stock Titan
Protara Therapeutics (TARA) awards director 31,000 stock options at $3.94 - Stock Titan
Protara Therapeutics (TARA) director awarded 31,000 stock options at $3.94 strike - Stock Titan
Cynthia Smith granted 31,000 stock options at Protara Therapeutics (TARA) - Stock Titan
Jane Huang awarded 31,000 Protara (TARA) stock options as director grant - Stock Titan
Protara (TARA) director awarded 31,000 options at $3.94 strike - Stock Titan
Director at Protara Therapeutics (NASDAQ: TARA) awarded 31,000 stock options at $3.94 - Stock Titan
Protara (TARA) director receives 31,000 stock options at $3.94 strike - Stock Titan
Protara Therapeutics Stockholders Approve Governance and Share Increases - TipRanks
Protara Therapeutics (TARA) investors approve share increase and pay items - Stock Titan
Protara Therapeutics Inc. (TARA) Gains 1.41% as Stock Nears Key ResistanceRevenue Weighted - newsline.com
Protara Therapeutics (TARA) Q1 2026 Earnings: Narrower-than-Expected Loss Drives Stock GainTangible Book Value - newsline.com
Protara Therapeutics (TARA) Dips 3.8% as Stock Nears Key Support LevelTrend Following Picks - newsline.com
Protara Therapeutics Q1 2026 Earnings: EPS Beat Driven by Expense Management, Stock SlipsStrong Earnings Momentum - newsline.com
TARA Q1 2026 Earnings: Narrower-Than-Expected Loss of -$0.31 per Share as Clinical Pipeline Advances - dars.gov.et
Protara Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift SentimentProduct Revenue Analysis - newsline.com
Protara Therapeutics (NASDAQ: TARA) CCO has 6,008 RSU shares withheld for taxes - Stock Titan
Protara Therapeutics Inc (TARA) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):